Hansoh Pharmaceutical (03692.HK) Surges Over 7% as Full-Year Net Profit Rises 27.07% and Innovative Drug Revenue Share Hits 82%

According to the Zhicheng Finance APP, Hansoh Pharma (03692) rose over 7%. As of press time, it was up 6.89%, trading at HK$35.36, with a turnover of HK$193 million.

On the news front, Hansoh Pharma recently released its 2025 annual performance. The group achieved revenue of 15.028 billion yuan (RMB, same below), representing a year-on-year increase of 22.57%; profit attributable to owners of the parent company was 5.555 billion yuan, a year-on-year increase of 27.07%; a final dividend of 20.00 Hong Kong cents per share is proposed. Notably, for the year ended December 31, 2025, revenue from innovative drugs and collaboration products amounted to approximately RMB 12.354 billion, accounting for about 82.2% of total revenue, becoming the core driver for the sustainable growth of the group's performance.